Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.
2.

Higher efficiency tandem solar cells through composite-cell current matching.

Garrison R, Kleiman R.

Opt Express. 2019 Apr 15;27(8):A543-A571. doi: 10.1364/OE.27.00A543.

PMID:
31053028
3.

Single-beam lifetime measurements via self-induced optical absorption.

Boyd KMW, Kleiman RN.

Opt Express. 2019 Feb 18;27(4):4445-4461. doi: 10.1364/OE.27.004445.

PMID:
30876063
4.

Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.

Engle SJ, Blaha L, Kleiman RJ.

Neuron. 2018 Nov 21;100(4):783-797. doi: 10.1016/j.neuron.2018.10.033. Review.

PMID:
30465765
5.

De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome.

Torres A, Brownstein CA, Tembulkar SK, Graber K, Genetti C, Kleiman RJ, Sweadner KJ, Mavros C, Liu KX, Smedemark-Margulies N, Maski K, Yang E, Agrawal PB, Shi J, Beggs AH, D'Angelo E, Lincoln SH, Carroll D, Dedeoglu F, Gahl WA, Biggs CM, Swoboda KJ, Berry GT, Gonzalez-Heydrich J.

Mol Genet Metab Rep. 2018 Jun 15;16:23-29. doi: 10.1016/j.ymgmr.2018.06.001. eCollection 2018 Sep.

6.

Using Machine Learning Algorithms to Predict Risk for Development of Calciphylaxis in Patients with Chronic Kidney Disease.

Kleiman RS, LaRose ER, Badger JC, Page D, Caldwell MD, Clay JA, Peissig PL.

AMIA Jt Summits Transl Sci Proc. 2018 May 18;2017:139-146. eCollection 2018.

7.

Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, LaChapelle EA, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2018 Apr 26;61(8):3753. doi: 10.1021/acs.jmedchem.8b00475. Epub 2018 Apr 6. No abstract available.

PMID:
29624389
8.

Translating genetic and preclinical findings into autism therapies.

Chahrour M, Kleiman RJ, Manzini MC.

Dialogues Clin Neurosci. 2017 Dec;19(4):335-343. Review.

9.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX.

J Med Chem. 2018 Feb 8;61(3):1001-1018. doi: 10.1021/acs.jmedchem.7b01466. Epub 2018 Jan 16.

PMID:
29293004
10.

Procedure to decouple reflectance and down-shifting effects in luminescent down-shifting enhanced photovoltaics.

Gabr AM, Walker AW, Wilkins MM, Kleiman R, Hinzer K.

Opt Express. 2017 Jun 12;25(12):A530-A538. doi: 10.1364/OE.25.00A530.

PMID:
28788883
11.

Prevention of sudden cardiac death in the young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium.

Idriss SF, Berger S, Harmon KG, Kindman A, Kleiman R, Lopez-Anderson M, Molossi S, Saarel TE, Strnadova C, Todaro T, Shinagawa K, Morrow V, Krucoff M, Vetter V, Wright TJ.

Am Heart J. 2017 Aug;190:123-131. doi: 10.1016/j.ahj.2017.05.003. Epub 2017 May 18. Review.

PMID:
28760206
12.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2017 Jul 13;60(13):5673-5698. doi: 10.1021/acs.jmedchem.7b00397. Epub 2017 Jun 16. Erratum in: J Med Chem. 2018 Apr 26;61(8):3753.

PMID:
28574706
13.

Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.

Piccini JP, Clark RL, Kowey PR, Mittal S, Dunnmon P, Stockbridge N, Reiffel JA, Turakhia MP, Ziegler PD, Kleiman RB, Ismat F, Sager P.

Am Heart J. 2017 May;187:156-169. doi: 10.1016/j.ahj.2017.01.012. Epub 2017 Jan 26. Review.

PMID:
28454799
14.

Current Perspectives in Autism Spectrum Disorder: From Genes to Therapy.

Chahrour M, O'Roak BJ, Santini E, Samaco RC, Kleiman RJ, Manzini MC.

J Neurosci. 2016 Nov 9;36(45):11402-11410. Review.

15.

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A.

Alexander MS, Gasperini MJ, Tsai PT, Gibbs DE, Spinazzola JM, Marshall JL, Feyder MJ, Pletcher MT, Chekler EL, Morris CA, Sahin M, Harms JF, Schmidt CJ, Kleiman RJ, Kunkel LM.

Transl Psychiatry. 2016 Sep 27;6(9):e901. doi: 10.1038/tp.2016.174.

16.

A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia.

Smedemark-Margulies N, Brownstein CA, Vargas S, Tembulkar SK, Towne MC, Shi J, Gonzalez-Cuevas E, Liu KX, Bilguvar K, Kleiman RJ, Han MJ, Torres A, Berry GT, Yu TW, Beggs AH, Agrawal PB, Gonzalez-Heydrich J.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001008. doi: 10.1101/mcs.a001008.

17.

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis.

Egbert JR, Uliasz TF, Shuhaibar LC, Geerts A, Wunder F, Kleiman RJ, Humphrey JM, Lampe PD, Artemyev NO, Rybalkin SD, Beavo JA, Movsesian MA, Jaffe LA.

Biol Reprod. 2016 May;94(5):110. doi: 10.1095/biolreprod.115.135897. Epub 2016 Mar 23.

18.

Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reports.

Brownstein CA, Kleiman RJ, Engle EC, Towne MC, D'Angelo EJ, Yu TW, Beggs AH, Picker J, Fogler JM, Carroll D, Schmitt RC, Wolff RR, Shen Y, Lip V, Bilguvar K, Kim A, Tembulkar S, O'Donnell K, Gonzalez-Heydrich J.

Am J Med Genet A. 2016 May;170A(5):1165-73. doi: 10.1002/ajmg.a.37595. Epub 2016 Feb 16.

19.

Data gaps limit the translational potential of preclinical research.

Kleiman RJ, Ehlers MD.

Sci Transl Med. 2016 Jan 6;8(320):320ps1. doi: 10.1126/scitranslmed.aac9888. Review.

PMID:
26738793
20.

Benefits of Centralized ECG Reading in Clinical Oncology Studies.

Kleiman R, Litwin J, Morganroth J.

Ther Innov Regul Sci. 2016 Jan;50(1):123-129. doi: 10.1177/2168479015597729.

PMID:
30236011
21.

A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.

Adar L, Avisar N, Lammerich A, Kleiman RB, Spiegelstein O.

Drug Des Devel Ther. 2015 May 15;9:2653-62. doi: 10.2147/DDDT.S81799. eCollection 2015.

22.

Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.

Morganroth J, Wang Y, Thorn M, Kumagai Y, Harris S, Stockbridge N, Kleiman R, Shah R.

Br J Clin Pharmacol. 2015 Sep;80(3):446-59. doi: 10.1111/bcp.12684. Epub 2015 Jul 2.

23.

Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder.

Reinhart V, Bove SE, Volfson D, Lewis DA, Kleiman RJ, Lanz TA.

Neurobiol Dis. 2015 May;77:220-7. doi: 10.1016/j.nbd.2015.03.011. Epub 2015 Mar 18.

PMID:
25796564
24.

ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.

Shah RR, Morganroth J, Kleiman RB.

Br J Clin Pharmacol. 2015 Mar;79(3):456-64. doi: 10.1111/bcp.12477. No abstract available.

25.

Spatio-temporal texture (SpTeT) for distinguishing vulnerable from stable atherosclerotic plaque on dynamic contrast enhancement (DCE) MRI in a rabbit model.

Wan T, Madabhushi A, Phinikaridou A, Hamilton JA, Hua N, Pham T, Danagoulian J, Kleiman R, Buckler AJ.

Med Phys. 2014 Apr;41(4):042303. doi: 10.1118/1.4867861.

26.

Replacing the thorough QT study: reflections of a baby in the bath water.

Kleiman RB, Shah RR, Morganroth J.

Br J Clin Pharmacol. 2014 Aug;78(2):195-201. doi: 10.1111/bcp.12296. No abstract available.

27.

Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain.

Kelly MP, Adamowicz W, Bove S, Hartman AJ, Mariga A, Pathak G, Reinhart V, Romegialli A, Kleiman RJ.

Cell Signal. 2014 Feb;26(2):383-97. doi: 10.1016/j.cellsig.2013.10.007. Epub 2013 Oct 31.

PMID:
24184653
28.

On Crowd-verification of Biological Networks.

sbv IMPROVER project team (in alphabetical order), Ansari S, Binder J, Boue S, Di Fabio A, Hayes W, Hoeng J, Iskandar A, Kleiman R, Norel R, O'Neel B, Peitsch MC, Poussin C, Pratt D, Rhrissorrakrai K, Schlage WK, Stolovitzky G, Talikka M.

Bioinform Biol Insights. 2013 Oct 10;7:307-25. doi: 10.4137/BBI.S12932. eCollection 2013.

29.

A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing.

Hu X, Zhang B, Liu W, Paciga S, He W, Lanz TA, Kleiman R, Dougherty B, Hall SK, McIntosh AM, Lawrie SM, Power A, John SL, Blackwood D, St Clair D, Brandon NJ.

Mol Psychiatry. 2014 Aug;19(8):857-8. doi: 10.1038/mp.2013.131. Epub 2013 Oct 15. No abstract available.

30.

Immunohistochemical characterization of axonal sprouting in mice.

Feeney EJ, Stephenson D, Kleiman R, Bove S, Cron C, Moody L, Robinson M, Ramirez JJ.

Restor Neurol Neurosci. 2013;31(5):517-31. doi: 10.3233/RNN-130311.

PMID:
23756540
31.

The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development.

Nada A, Gintant GA, Kleiman R, Gutstein DE, Gottfridsson C, Michelson EL, Strnadova C, Killeen M, Geiger MJ, Fiszman ML, Koplowitz LP, Carlson GF, Rodriguez I, Sager PT.

Am Heart J. 2013 Apr;165(4):489-500. doi: 10.1016/j.ahj.2013.01.011. Epub 2013 Feb 21. Review.

PMID:
23537964
32.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, Lui S, Kleiman RJ, Vanase-Frawley M, Schmidt AW, Menniti F, Schmidt CJ, Hoffman WE, Hajos M, McDowell L, O'Connor RE, Macdougall-Murphy M, Fonseca KR, Becker SL, Nelson FR, Liras S.

J Med Chem. 2012 Nov 8;55(21):9055-68. doi: 10.1021/jm3009635. Epub 2012 Oct 12.

PMID:
23025719
33.

The distribution of phosphodiesterase 2A in the rat brain.

Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O'Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS.

Neuroscience. 2012 Dec 13;226:145-55. doi: 10.1016/j.neuroscience.2012.09.011. Epub 2012 Sep 19.

34.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S.

J Med Chem. 2012 Nov 8;55(21):9045-54. doi: 10.1021/jm3007799. Epub 2012 Jul 25.

PMID:
22780914
35.

Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma.

Lanz TA, Bove SE, Pilsmaker CD, Mariga A, Drummond EM, Cadelina GW, Adamowicz WO, Swetter BJ, Carmel S, Dumin JA, Kleiman RJ.

Biomarkers. 2012 Sep;17(6):524-31. doi: 10.3109/1354750X.2012.694476. Epub 2012 Jun 7.

PMID:
22672085
36.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
37.

MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function.

Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, Roth RH, Edbauer D, Kleiman RJ, Wahlestedt C.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3125-30. doi: 10.1073/pnas.1113793109. Epub 2012 Feb 6.

38.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

PMID:
20923867
39.

Review of multi-person exposure calls to a regional poison control center.

Morgan BW, Skinner CG, Kleiman RJ, Geller RJ, Chang AS.

West J Emerg Med. 2010 Aug;11(3):291-3.

40.

Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.

Min SS, Turner JR, Nada A, DiMino TL, Hynie I, Kleiman R, Kowey P, Krucoff MW, Mason JW, Phipps A, Newton-Cheh C, Pordy R, Strnadova C, Targum S, Uhl K, Finkle J.

Am Heart J. 2010 May;159(5):716-29. doi: 10.1016/j.ahj.2010.02.004. Review.

PMID:
20435178
41.

Therapeutics for cognitive aging.

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM.

Ann N Y Acad Sci. 2010 Apr;1191 Suppl 1:E1-15. doi: 10.1111/j.1749-6632.2010.05532.x.

42.

Chronic treatment with a selective inhibitor of casein kinase I delta/epsilon yields cumulative phase delays in circadian rhythms.

Sprouse J, Reynolds L, Kleiman R, Tate B, Swanson TA, Pickard GE.

Psychopharmacology (Berl). 2010 Jul;210(4):569-76. doi: 10.1007/s00213-010-1860-5. Epub 2010 Apr 21.

PMID:
20407760
43.

Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S.

J Med Chem. 2009 Dec 24;52(24):7946-9. doi: 10.1021/jm9015334.

PMID:
19919087
45.

Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species.

Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O'Donnell MM, Muravnick KB, Menniti FS, Kleiman RJ, Morton D.

J Histochem Cytochem. 2009 Oct;57(10):933-49. doi: 10.1369/jhc.2009.953471. Epub 2009 Jun 8.

46.

Update on research and activities at the Centers for Disease Control and Prevention, and the agency for toxic substances and disease registry.

Kleiman R, Rentz ED, Teshale E, Thompson N, Schurz-Rogers H.

J Med Toxicol. 2008 Sep;4(3):197-200. No abstract available.

47.

An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions.

Badura L, Swanson T, Adamowicz W, Adams J, Cianfrogna J, Fisher K, Holland J, Kleiman R, Nelson F, Reynolds L, St Germain K, Schaeffer E, Tate B, Sprouse J.

J Pharmacol Exp Ther. 2007 Aug;322(2):730-8. Epub 2007 May 14.

PMID:
17502429
48.

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.

Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT.

J Histochem Cytochem. 2006 Nov;54(11):1205-13. Epub 2006 Jul 24.

PMID:
16864896
49.

Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT, Kleiman RJ, Loveridge AH, Lundeen EB, Newman SL, Noboa JA, Miegs DP, O'Beirne KA, Philpot KB, Schultz MN, Valente MC, Wiebers MR, Swenson ER.

High Alt Med Biol. 2006 Spring;7(1):17-27.

PMID:
16544963
50.

Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS.

Neuroscience. 2006 May 12;139(2):597-607. Epub 2006 Feb 17.

Supplemental Content

Loading ...
Support Center